Genflow Biosciences plc (GENFF)

Market Cap	14.63M +242.8%
Revenue (ttm)	788.17K +82.7%
Net Income	-1.91M
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	909
Open	0.0545
Previous Close	n/a
Day's Range	0.0545 - 0.0545
52-Week Range	0.0100 - 0.0711
Beta	2.30
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 28, 2026

About Genflow Biosciences

Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapies in the United Kingdom, Belgium, and the United States. It develops drugs in pre-clinical trial stage, including GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion for the treatment of metabolic associated steatohepatitis; GF-1003, a topical delivery of SIRT6 to the skin; GF-1004, a non-human pipeline anti-aging for veterinary use; GF-1005 for the treatment of mitochondrial dysfunct...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Employees: 5
• Stock Exchange: OTCMKTS
• Ticker Symbol: GENFF

Financial Performance

In 2025, Genflow Biosciences's revenue was 585,607, an increase of 82.73% compared to the previous year's 320,471. Losses were -1.42 million, -10.69% less than in 2024.

Financial numbers in GBP

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 21, 2026

Data Sources Report a data error